Home » Newsletters » BioWorld Science

BioWorld Science

July 24, 2006

View Archived Issues

Fluoglizine more potent than fluoxetine in a mouse model of depression/anxiety

Neuroprotective effects of RWJ-333369 shown in a rat status epilepticus model

Emisphere and Roche establish multiproduct research collaboration

Inex to complete spin-out of Tekmira in September

Russian sites cleared to participate in BiovaxID phase III study

Xceleron to conduct phase 0 microdose study for Biofrontera Bioscience

Nerviano Medical Sciences to scale up Indena compounds

DNAPrint Genomics signs research agreement with Beth Israel Deaconess

DAC selects Evotec as partner for Hsp90 discovery project

ProtoKinetix' AAGP protects cells while preserving normal cell function

Alteon shareholders approve HaptoGuard merger

ImClone and Merck amend and supplement Erbitux agreement

New phase II study evaluates HGS-ETR1 with bortezomib in multiple myeloma

AVI BioPharma modifies HCV study of AVI-4065

CF-101 begins phase IIb for rheumatoid arthritis

CellTran and Innogenetics negotiate combining wound care activities

Nikken Chemical launches Selenica R tablet 400 mg in Japan

New glia-targeting clinical candidate presented with efficacy in AD

Nexavar approved in Europe for advanced renal cell carcinoma

New agents for treating neurological disorders disclosed in recent patent literature

Novel therapeutic agents for metabolic disorders reported

Symbicort receives FDA approval

New TGF-beta antagonists prepared and tested by Korean scientists

Tysabri available in U.S. for relapsing MS

TaiGen Biotechnology reports initial preclinical data of its novel agent against SARS virus

Tygacil now available in U.K.

Lansoprazole in chronic postnasal drip to be evaluated in clinical study / News in Context

Important antinociceptive actions of PPC-5383, a novel acid-sensing ion channel blocker

Promising preclinical results of novel Abeta fibril-disrupting agents developed at ProteoTech

Protective effects of dactylorhin B against beta amyloid-induced brain mitochondrial toxicity

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...